We read with great interest the case report by Omuro et al, 1 which describes the regression of an unresectable pancreatic tumor, following nonmyeloablative allogenic peripheralblood stem-cell transplantation. The authors hypothesize that a graft vs tumor effect might have determined the favorable clinical response.
Due to the obvious expectations that this case report might generate in those who daily face an otherwise rapidly lethal disease, we would like to call for caution while making a few comments on the specific case.
First, a pathological assessment of the pancreatic tumor is missing. The adenocarcinoma cells found at fine-needle aspiration cytology cannot discriminate between ductal pancreatic cancer and other pancreatic tumors which are known to have a substantially different biological and clinical course. In fact, we do not know whether the authors' statement 'this pancreatic tumor was not a typical pancreatic duct cell carcinoma' refers to nonreported immunocytological features of the neoplastic cells, rather than to the diagnostic pattern of this case (no abnormality in serum markers and absolutely peculiar CT findings). In particular, based on the presented imaging, one cannot rule out a mucinous cystic neoplasia as the disease possibly affecting this woman of middle age.
Furthermore, a molecular characterization of this pancreatic tumor would be extremely helpful in trying to define an immunological mechanism that might possibly account for the observed clinical response. Mutations at K-RAS codon 12, which occur almost invariably in ductal pancreatic cancer but less frequently in other pancreatic exocrine tumors, 2 have been recently found to determine T-cell immunity against tumoral K-RAS peptides in patients with pancreatic cancer. 3 The vaccination of a patient with pancreatic cancer with 17-mer mutant ras peptides has been also demonstrated to induce an HLA-A3-restricted T-lymphocyte peripheral response. 4 On the other hand, in one of the few pancreatic cancers with microsatellite instability, 5 TGFbRII mutated proteins might act as epitopes determining a cytotoxic lymphocyte response. 6 In any event, to know the molecular features of a pancreatic tumor which had such a dramatic response to allogenic stem-cell transplantation would help those clinical investigators who might desire to offer this therapeutic option to other patients with unresectable pancreatic cancer. This case report enables us to include pancreatic cancer, or at least a given subset, among solid tumors which appear to be suceptible to immunologic control. Thus, to identify target antigens toward which chimeric T-cells may exert their cytotoxic effect becomes an emerging priority in pancreatic cancer research. 
